Planet DDS vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-native dental practice management including Denticon for DSOs and Apteryx XVWeb for cloud imaging. Irvine CA; founded 2003;
About
Planet DDS is an Irvine, California-based cloud-native dental software company that offers an integrated suite of tools for dental practices, DSOs, and dental imaging, with Denticon as its flagship cloud practice management system and Apteryx XVWeb as its cloud imaging platform. Founded in 2003, Planet DDS built Denticon as one of the first true multi-site, cloud-based dental practice management systems at a time when the market was dominated by legacy on-premise software. Denticon's multi-location architecture allows DSOs and group practices to manage enterprise-level functions—credentialing, reporting, fee schedule management, and patient record sharing across locations—from a centralized cloud platform rather than managing separate on-premise installations at each site.\n\nPlanet DDS has doubled down on the DSO market, where its cloud architecture offers significant operational advantages over legacy systems that require local servers, manual software updates, and location-by-location IT support. The company's acquisition of Apteryx, a dental imaging software business, extended its platform into digital radiography management, allowing practices to manage both clinical workflows and imaging through an integrated cloud environment. Planet DDS also acquired Legwork in 2021, a dental patient communication and marketing platform, adding patient engagement, online scheduling, and reputation management capabilities to its suite.\n\nThe DSO market has been growing rapidly as dental consolidation accelerates, and Planet DDS is positioned to benefit from practices migrating away from Dentrix and Eaglesoft to cloud-native platforms that can scale with multi-location growth. The company integrates with dental imaging sensors, intraoral cameras, and third-party lab management systems. Planet DDS competes with Carestream Dental, Curve Dental, and the Carestream/Apteryx imaging market alongside practice management leaders Dentrix and Eaglesoft, which are owned by Henry Schein.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.